Vimian Group AB (publ) (VIMGF)
Vimian Group AB (publ) operates in the Medical - Diagnostics & Research industry of the Healthcare sector, headquartered in Stockholm, AB, SE. The stock last traded at $2.77, up 0.00% on the session, giving a market capitalisation of $1.46B. On trailing twelve-month figures it carries a trailing P/E of 45.94, a net margin of 8.2%. Its beta of 1.19 implies it has historically moved more than the broad market.
Vimian Group AB (publ) is an international enterprise focused on the animal health sector, organized into four distinct divisions: Specialty Pharma, MedTech, Diagnostics, and Veterinary Services. The company offers a range of proprietary diagnostic tools and treatments under its Nextmune brand, providing both prescription and non-prescription options for the preventive care and management of chronic conditions in companion animals. Through its Indical Bioscience brand, Vimian delivers sophisticated molecular and immunodiagnostic solutions for laboratories, specifically targeting veterinary applications for both livestock and companion animal health markets. Moreover, its VetFamily brand operates a membership-based platform that provides veterinary clinics with procurement services, tech-enabled operations including online marketing, education, and HR support, as well as a professional community. The company also supplies orthopedic implants to veterinarians and universities through its Movora brand. Established in 2020, Vimian Group is based in Stockholm, Sweden.
Vimian Group AB (publ) is most often compared with the following Healthcare names: